12.85 % to Target, Morgan Stanley Reconfirms ‘”Overweight”’ Rating on BeiGene (BGNE) Shares Today

March 21, 2018 - By Vivian Park

 12.85 % to Target, Morgan Stanley Reconfirms ‘

BeiGene (BGNE) Rating Reaffirmed

In analysts report issued to clients on 21 March, The “Overweight” rating of BeiGene (BGNE) shares was reiterated by Morgan Stanley, who now has a $200 TP on the stock. Morgan Stanley’s TP means a possible upside of 12.85 % from the stock close price of the company.

BeiGene, Ltd. (NASDAQ:BGNE) Ratings Coverage

Among 5 analysts covering BeiGene (BGNE), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. BeiGene has $200.0 highest and $41.0 lowest target. $112.60’s average target is -36.46% below currents $177.22 stock price. BeiGene had 15 analyst reports since September 22, 2016 according to SRatingsIntel. Robert W. Baird downgraded the stock to “Neutral” rating in Tuesday, November 14 report. Cowen & Co maintained the stock with “Buy” rating in Friday, June 16 report. The stock of BeiGene, Ltd. (NASDAQ:BGNE) has “Buy” rating given on Wednesday, July 5 by Maxim Group. Cowen & Co maintained the shares of BGNE in report on Monday, January 8 with “Buy” rating. Ladenburg initiated the stock with “Buy” rating in Monday, August 7 report. The rating was maintained by Maxim Group with “Buy” on Thursday, June 29. The rating was maintained by Cowen & Co on Wednesday, June 7 with “Buy”. The stock has “Buy” rating by Maxim Group on Thursday, September 22. Maxim Group maintained it with “Buy” rating and $5200 target in Wednesday, June 14 report. The rating was maintained by Maxim Group on Monday, June 5 with “Buy”.

The stock increased 2.93% or $5.05 during the last trading session, reaching $177.22. About 654,290 shares traded or 80.45% up from the average. BeiGene, Ltd. (BGNE) has risen 36.36% since March 21, 2017 and is uptrending. It has outperformed by 19.66% the S&P500.

Analysts await BeiGene, Ltd. (NASDAQ:BGNE) to report earnings on May, 9. They expect $-1.94 EPS, down 52.76 % or $0.67 from last year’s $-1.27 per share. After $-2.19 actual EPS reported by BeiGene, Ltd. for the previous quarter, Wall Street now forecasts -11.42 % EPS growth.

BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops molecularly-targeted and immuno-oncology drugs for the treatment of cancer. The company has market cap of $9.43 billion. The company's clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations. It currently has negative earnings. The Company’s preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.